Urine test for prostate cancer: Study

June 25, 2017

One limitation of the study is that most patients were Caucasian, so further studies are needed to see whether the findings extend to all men, the researchers noted. Although not yet available to the public, the test soon will be offered at the University of Michigan, Tomlins said. The test is licensed to Gen-Probe, a San Diego maker of genetically based diagnostic tests. Mike Watt, a company spokesman, said the test is still in the early stages of development and has not been submitted to the U.S. Food and Drug Administration for approval. The company has no firm idea of the test's cost should it be approved, Watt added. Study funding was supported in part by Gen Probe, and the University of Michigan and Brigham and Women??ôs Hospital have obtained a patent on the detection of ETS gene fusion in prostate cancer, in which four co-authors are listed as co-inventors.

According to prostate cancer expert, Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston the test is ???a step forward, but we still have a ways to go.??? D'Amico said, ???On average the risk is higher in people with both markers and lowest in people who have neither, but that's on average.??? If a patient has indications of an aggressive prostate cancer, the test can add more to that diagnosis, D'Amico said. But for men who potentially have cancer, a low-risk determination based on this test shouldn't preclude biopsy, he said. More than 1 million men have their prostates biopsied every year in the U.S.